Brief description of indications and correct medication guide for erdafitinib

Erdafitinib, an innovative targeted anti-cancer drug, has achieved remarkable results in the treatment of specific types of cancer in recent years, especially for cancer patients carryingFGFR2 or FGFR3 gene mutations, it has brought new treatment hope. This article will introduce in detail who is suitable for erdafitinib and how to use this drug correctly.

1. Applicable groups of erdafitinib

Erdafitinib is mainly indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC), and these patients must meet the following conditions: have specific changes in the FGFR3 or FGFR2 gene, and have disease progression during previous platinum-based chemotherapy, including disease progression within 12 months after neoadjuvant or adjuvant platinum-based chemotherapy. To ensure treatment is targeted, patients should be screened with an FDA-approved companion diagnostic for erdafitinib.

2. Correct use of erdafitinib

To ensure optimal efficacy of erdafitinib, patients must follow the correct usage instructions below:

1. Genetic testing: Before starting erdafitinib treatment, patients must undergo genetic testing to confirm the presence of mutations in the FGFR2 or FGFR3 gene in tumor specimens.

2. Dose adjustment: The recommended initial dose is 8 mg once daily. On days 14 to 21 after the initial dose of treatment, the doctor will evaluate the need to increase the dose to 9 mg each time based on the patient's blood phosphorus level.

3. Medication instructions: Erdafitinib is an oral preparation and can be taken with food or alone. Patients should swallow the tablets whole and avoid chewing or crushing.

4. Monitoring and follow-up: During treatment, doctors will regularly follow up with patients to monitor the efficacy of the drug and possible side effects. Patients should actively cooperate with relevant examinations, such as blood tests, liver function and kidney function tests, so that any potential problems can be discovered and dealt with in a timely manner.

5. Note: Erdafitinib may cause a series of side effects, such as fatigue, nausea, diarrhea, dry mouth, etc. Patients should contact their doctor immediately if they experience any discomfort and seek appropriate treatment. In addition, because erdafitinib has embryo-fetal toxicity, patients of childbearing age should take effective contraceptive measures during treatment and within 1 month after the last dose of the drug, and consult a doctor to choose a suitable contraceptive method.

In short, erdafitinib, as a targeted treatment drug targeting FGFR gene mutations, has demonstrated significant therapeutic effects in specific cancer patients. However, to ensure patient safety and therapeutic efficacy, correct use and strict monitoring and follow-up are crucial. Patients should use medications rationally under the guidance of doctors and pay close attention to their own conditions so that treatment plans can be adjusted in a timely manner. Currently, erdafitinib is only marketed overseas, and the price of the original drug is relatively high. But fortunately, affordable generic drug options are available in places like Laos, giving patients more treatment options.